Based on the presented results, in addition to the prophylactic model, this formulation may hold promise for developing a therapeutic vaccine in the HER2 positive breast cancer in the presence of an appropriate adjuvant and/or CD4 restricted peptides such as PADRE. This evidence concerns the gene ERBB2 and breast carcinoma.